JP6490660B2 - 活性に基づくプローブの化合物、組成物、および使用方法 - Google Patents

活性に基づくプローブの化合物、組成物、および使用方法 Download PDF

Info

Publication number
JP6490660B2
JP6490660B2 JP2016503301A JP2016503301A JP6490660B2 JP 6490660 B2 JP6490660 B2 JP 6490660B2 JP 2016503301 A JP2016503301 A JP 2016503301A JP 2016503301 A JP2016503301 A JP 2016503301A JP 6490660 B2 JP6490660 B2 JP 6490660B2
Authority
JP
Japan
Prior art keywords
compound
group
compound according
probe
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016503301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518341A (ja
JP2016518341A5 (cg-RX-API-DMAC7.html
Inventor
マシュー エス. ボギョー,
マシュー エス. ボギョー,
マルテイン フェルドウス,
マルテイン フェルドウス,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2016518341A publication Critical patent/JP2016518341A/ja
Publication of JP2016518341A5 publication Critical patent/JP2016518341A5/ja
Application granted granted Critical
Publication of JP6490660B2 publication Critical patent/JP6490660B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2016503301A 2013-03-15 2014-03-15 活性に基づくプローブの化合物、組成物、および使用方法 Active JP6490660B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794296P 2013-03-15 2013-03-15
US61/794,296 2013-03-15
PCT/US2014/029990 WO2014145257A2 (en) 2013-03-15 2014-03-15 Activity-based probe compounds, compositions, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019034163A Division JP2019081791A (ja) 2013-03-15 2019-02-27 活性に基づくプローブの化合物、組成物、および使用方法

Publications (3)

Publication Number Publication Date
JP2016518341A JP2016518341A (ja) 2016-06-23
JP2016518341A5 JP2016518341A5 (cg-RX-API-DMAC7.html) 2017-04-20
JP6490660B2 true JP6490660B2 (ja) 2019-03-27

Family

ID=51538442

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016503301A Active JP6490660B2 (ja) 2013-03-15 2014-03-15 活性に基づくプローブの化合物、組成物、および使用方法
JP2019034163A Withdrawn JP2019081791A (ja) 2013-03-15 2019-02-27 活性に基づくプローブの化合物、組成物、および使用方法
JP2021005558A Withdrawn JP2021059606A (ja) 2013-03-15 2021-01-18 活性に基づくプローブの化合物、組成物、および使用方法
JP2023060174A Active JP7689753B2 (ja) 2013-03-15 2023-04-03 活性に基づくプローブの化合物、組成物、および使用方法
JP2025084936A Pending JP2025124721A (ja) 2013-03-15 2025-05-21 活性に基づくプローブの化合物、組成物、および使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019034163A Withdrawn JP2019081791A (ja) 2013-03-15 2019-02-27 活性に基づくプローブの化合物、組成物、および使用方法
JP2021005558A Withdrawn JP2021059606A (ja) 2013-03-15 2021-01-18 活性に基づくプローブの化合物、組成物、および使用方法
JP2023060174A Active JP7689753B2 (ja) 2013-03-15 2023-04-03 活性に基づくプローブの化合物、組成物、および使用方法
JP2025084936A Pending JP2025124721A (ja) 2013-03-15 2025-05-21 活性に基づくプローブの化合物、組成物、および使用方法

Country Status (7)

Country Link
US (4) US10100037B2 (cg-RX-API-DMAC7.html)
EP (2) EP4218829A3 (cg-RX-API-DMAC7.html)
JP (5) JP6490660B2 (cg-RX-API-DMAC7.html)
KR (1) KR102279618B1 (cg-RX-API-DMAC7.html)
CN (2) CN120132004A (cg-RX-API-DMAC7.html)
ES (1) ES2938225T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014145257A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4218829A3 (en) * 2013-03-15 2023-08-16 The Board of Trustees of the Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
EP3204352B1 (en) 2014-10-06 2020-07-01 Cortexyme, Inc. Inhibitors of lysine gingipain
CN107406872B (zh) * 2015-01-22 2023-03-28 里兰斯坦福初级大学理事会 用于标记动物组织的化合物、组合物及其应用
EP3374352A4 (en) 2015-11-09 2019-10-02 Cortexyme, Inc. GINGIPAINE ARGININE INHIBITORS
IL265389B1 (en) 2016-09-16 2026-07-01 Quince Therapeutics Inc Ketone compounds lysine inhibitors gingerapine, preparations containing them and uses thereof
WO2018071556A1 (en) 2016-10-11 2018-04-19 The Regents Of The University Of California Detection, identification, and purification of degradative and non-degradative enzymes in biological samples
CN116217656B (zh) * 2016-12-23 2026-05-08 里兰斯坦福初级大学理事会 基于活性的探针化合物、组合物及其使用方法
CN110678460A (zh) * 2017-03-30 2020-01-10 里兰斯坦福初级大学理事会 用于体内成像的蛋白酶激活的造影剂
WO2018200592A1 (en) 2017-04-24 2018-11-01 Regents Of The University Of California Biosynthesis of bioorthogonal amino acids
EP3717019A4 (en) * 2017-11-28 2021-09-22 Board of Regents of the University of Nebraska RADIOPHARMACEUTICALS AND METHOD OF USE THEREOF
WO2020028396A1 (en) 2018-07-30 2020-02-06 Georgetown University Chirality sensing with molecular click chemistry probes
US11860084B2 (en) 2018-09-11 2024-01-02 Georgetown University Quantitative auxiliary-free chirality sensing with a metal probe
CA3120758A1 (en) * 2018-12-20 2020-06-25 Takeda Pharmaceutical Company Limited Novel activity-based probes for neutrophil elastase and their use
CA3120756A1 (en) * 2018-12-20 2020-06-25 Takeda Pharmaceutical Company Limited Sulfoxonium ylide derivatives as probes for cysteine protease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US5055451A (en) 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
WO1996041638A1 (en) 1995-06-13 1996-12-27 Sanofi Winthrop, Inc. Calpain inhibitors for the treatment of neurodegenerative diseases
US5989823A (en) 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6544951B2 (en) * 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
WO2000064988A1 (en) 1999-04-23 2000-11-02 Molecular Probes, Inc. Xanthene dyes and their application as luminescence quenching compounds
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US20020052323A1 (en) * 2000-08-30 2002-05-02 Jinhai Wang Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents
GB0112868D0 (en) 2001-05-25 2001-07-18 Secr Defence Detection system
US20050014160A1 (en) 2003-07-18 2005-01-20 Sriram Kumaraswamy Assays for protease enzyme activity
US8968700B2 (en) 2005-08-11 2015-03-03 The Board Of Trustees Of The Leland Stanford Junior University Imaging of protease activity in live cells using activity based probes
US8343458B2 (en) 2008-04-03 2013-01-01 The Board Of Trustees Of The Leland Stanford Junior University Probes for in vivo targeting of active cysteine proteases
WO2012021800A2 (en) * 2010-08-13 2012-02-16 Banyan Biomarkers Caspase inhibitors as therapeutics for neural and organ injury and imaging
US9180209B2 (en) * 2011-02-28 2015-11-10 The Board Of Trustees Of The Leland Stanford Junior University Non-peptidic quenched fluorescent imaging probes
WO2014152389A1 (en) 2013-03-14 2014-09-25 Lumicell, Inc. Imaging agent for detection of diseased cells
EP4218829A3 (en) * 2013-03-15 2023-08-16 The Board of Trustees of the Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
CN116217656B (zh) * 2016-12-23 2026-05-08 里兰斯坦福初级大学理事会 基于活性的探针化合物、组合物及其使用方法

Also Published As

Publication number Publication date
JP2025124721A (ja) 2025-08-26
US20230391750A1 (en) 2023-12-07
US20210284626A1 (en) 2021-09-16
WO2014145257A2 (en) 2014-09-18
US20160039792A1 (en) 2016-02-11
KR20150129004A (ko) 2015-11-18
EP4218829A2 (en) 2023-08-02
US11655236B2 (en) 2023-05-23
EP2971065B1 (en) 2022-12-14
US20190270722A1 (en) 2019-09-05
US10100037B2 (en) 2018-10-16
JP2016518341A (ja) 2016-06-23
JP7689753B2 (ja) 2025-06-09
KR102279618B1 (ko) 2021-07-20
EP2971065A2 (en) 2016-01-20
US10829477B2 (en) 2020-11-10
ES2938225T3 (es) 2023-04-05
JP2019081791A (ja) 2019-05-30
JP2021059606A (ja) 2021-04-15
CN120132004A (zh) 2025-06-13
WO2014145257A3 (en) 2014-12-31
EP2971065A4 (en) 2016-12-21
JP2023085423A (ja) 2023-06-20
CN105431546A (zh) 2016-03-23
EP4218829A3 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
JP7689753B2 (ja) 活性に基づくプローブの化合物、組成物、および使用方法
JP7720102B2 (ja) 活性ベースのプローブ化合物、組成物、および使用方法
JP2018511556A (ja) in vivo画像化のためのプロテアーゼ活性化コントラスト剤
JP7149614B2 (ja) in vivo画像化のためのプロテアーゼ活性化コントラスト剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190227

R150 Certificate of patent or registration of utility model

Ref document number: 6490660

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250